Pfizer's new hemophilia treatment drug Mataximab's application for market launch in China has been accepted
楚一帆
发表于 2024-8-13 10:09:17
217
0
0
On August 13th, the official website of the Drug Evaluation Center (CDE) of the China National Medical Products Administration (NMPA) announced that the Class 1 therapeutic biological product Mataximab Injection, declared by Pfizer, has been approved for listing in China. Marstacimab is a novel hemophilia treatment drug developed by Pfizer, which only requires subcutaneous injection once a week.
CandyLake.com 系信息发布平台，仅提供信息存储空间服务。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
转播
猜你喜欢
- Honda accelerates its electrification layout in China, with joint ventures intensively deploying electric vehicles
- Pfizer and CR Pharma reach strategic partnership on four mature drugs
- Merck PD-1 inhibitor pembrolizumab's fourth lung cancer indication approved in China
- The CEO of the world's fourth largest car company, Stellantis, has resigned and adjusted the person in charge of related business in China
- The CEO of the world's fourth largest car company, Stellantis, has resigned and adjusted the person in charge of related business in China
- Nvidia expands in China against the trend, attracting talent and adding hundreds of R&D personnel in one year
- Pfizer expects revenue of $61 billion to $64 billion in 2025, with an estimated $63.23 billion
- Apple is rumored to have preliminary discussions with Tencent and ByteDance to consider embedding their AI models into iPhones sold in China
- Eli Lilly's new Alzheimer's disease drug launched: annual drug cost exceeds $30000, Pfizer Roche is expanding its strategy
- Sanofi's BTK inhibitor is declared for market in China
